Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

by Adam Bohr, Thais Leite Nascimento, Necati Harmankaya, Johan Juhl Weisser, Yingya Wang, Holger Grohganz, Thomas Rades, Korbinian Löbmann
Published 2019-01-01